DoximityDOCS
DOCS
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
258% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 33
40% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 110
24% more capital invested
Capital invested by funds: $4.98B [Q3] → $6.18B (+$1.21B) [Q4]
23% more funds holding
Funds holding: 348 [Q3] → 427 (+79) [Q4]
20% more call options, than puts
Call options by funds: $125M | Put options by funds: $104M
0% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]
0.85% less ownership
Funds ownership: 91.26% [Q3] → 90.41% (-0.85%) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$55
9%
downside
Avg. target
$72
19%
upside
High target
$90
49%
upside
9 analyst ratings
4 positive
44%
5 neutral
56%
0 negative
0%
Mizuho Steven Valiquette 50% 1-year accuracy 3 / 6 met price target | 7%upside $65 | Neutral Maintained | 10 Feb 2025 |
Goldman Sachs David Roman 30% 1-year accuracy 6 / 20 met price target | 32%upside $80 | Neutral Maintained | 10 Feb 2025 |
Leerink Partners Michael Cherny 68% 1-year accuracy 19 / 28 met price target | 49%upside $90 | Outperform Upgraded | 7 Feb 2025 |
Canaccord Genuity Richard Close 46% 1-year accuracy 13 / 28 met price target | 17%upside $71 | Hold Maintained | 7 Feb 2025 |
Raymond James Brian Peterson 31% 1-year accuracy 8 / 26 met price target | 37%upside $83 | Outperform Reiterated | 7 Feb 2025 |
Financial journalist opinion
Based on 7 articles about DOCS published over the past 30 days
Positive
Zacks Investment Research
2 hours ago
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
Positive
Zacks Investment Research
5 days ago
Doximity (DOCS) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Doximity (DOCS) settling at $62.99, representing a +0.35% change from its previous close.
Positive
Investors Business Daily
1 week ago
Spotify, Rubrik Lead Five Growth Stocks Regaining This Key Level
Amid the market correction, few growth stocks are above their 50-day moving averages. Spotify, Rubrik lead five that have reclaimed that level.
Positive
Zacks Investment Research
2 weeks ago
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
Positive
Zacks Investment Research
2 weeks ago
Buy 5 High-Flying Health & Fitness Stocks Year to Date With More Upside
Five Health & Fitness stocks have strong growth potential for 2025. These are: GRMN, SFM, DOCS, LTH, VFC.
Positive
Zacks Investment Research
3 weeks ago
Is Doximity (DOCS) a Solid Growth Stock? 3 Reasons to Think "Yes"
Doximity (DOCS) possesses solid growth attributes, which could help it handily outperform the market.
Positive
Zacks Investment Research
4 weeks ago
5 Top-Ranked Stocks Poised for an Earnings Beat
Top-ranked stocks Tenet Healthcare (THC), Fortinet (FTNT), Lyft (LYFT), Garmin (GRMN) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
Neutral
MarketBeat
1 month ago
Market Shift: These 3 Stocks Are Winning While Big Tech Lags
As earnings season winds down, a notable trend has emerged in the markets: several mega-cap stocks have underperformed year-to-date (YTD). In contrast, several mid-to-large cap stocks with strong retail followings have delivered superior returns.
Neutral
Business Wire
1 month ago
DOXIMITY INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Doximity, Inc.'s Directors and Officers for Breach of Fiduciary Duties – DOCS
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Doximity, Inc. (“Doximity”) (NYSE: DOCS) breached their fiduciary duties to Doximity and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Doximity's board of directors or senior management failed to manage Doximity in an acceptable manner, in breach of their fiduciary dut.
Positive
Seeking Alpha
1 month ago
Doximity: Rating Downgrade As Near-Term Upside Is Priced In
I downgraded Doximity from buy to hold due to expected growth slowdown and current high valuation at 40.5x forward EBITDA. DOCS reported strong Q3 performance with $168.6 million revenue, 25% y/y growth, and 93.3% gross margin, driven by high pharma client demand. New ad products grew over 100% y/y, now contributing >20% of pharma revenue, showing strong underlying demand and expanding advertiser engagement.
Charts implemented using Lightweight Charts™